In one patient with a KRAS G12D tumor, we failed to detect mutations during the FNA-needle flush process, while we could identify the mutation using DNA that was purified and concentrated from the supernatant and water-bursting of the residual tissue in FNA-needles (Table 2; patient 8). Here, KRAS is linked to neoplasm.